Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseTherapies for Prevention and Treatment of Alzheimer's DiseaseTau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective StrategiesTau Biology and Tau-Directed Therapies for Alzheimer's DiseaseAlternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.Methylene blue and its analogues as antidepressant compounds.Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.Assays for the Screening and Characterization of Tau Aggregation Inhibitors.
P2860
Q26739412-9D56DA41-87C8-42E8-A891-E56A64E4A62BQ26740007-229550DA-CBA4-40DC-8190-7E3089A9A493Q26769957-D90AC0F2-068E-4592-B50A-3BB4A677FA86Q28071398-598E9EAF-00BB-48F1-85D3-DF3CFA2D64C1Q36913723-966F0D5B-CE58-497B-A905-CCA3BAE82909Q37511619-4F10A98A-9837-4F8D-A208-AAE38DB801CAQ38715233-7873047F-A65D-4614-9AA2-7789D08B08A3Q38901388-46769BF0-CD03-427C-837D-765C3F04CF79Q39035486-01FDE07F-43B6-48B1-B060-7E82DB09A00BQ46327960-C9CE9FCF-14F1-4648-A780-AA69133864E3Q47147322-6A969BC7-777F-4D94-8754-CFE38314E622Q47308968-ADF9B1C4-98F6-4EF3-A8D2-E7126F02A1B7Q47548619-8176F29E-8607-48F6-8893-6A12DDF7FB68Q48004149-659D8E5B-0A6D-42D5-92B1-7C4BA1757988Q48239696-62784309-C095-48B1-A790-3638FDC565FBQ50632272-6E04B00F-B80C-4E9B-98C1-E119CC970486Q51263470-E184AFEC-FF8E-4DE2-B569-601EBC885E94
P2860
Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@ast
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@en
type
label
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@ast
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@en
prefLabel
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@ast
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@en
P2093
P2860
P1476
Effects of oxidized and reduce ...... sgenic mouse tauopathy models.
@en
P2093
Charles R Harrington
Claude M Wischik
Claudia Zabke
David Horsley
Elizabeth A Goatman
Franz Theuring
Gernot Riedel
Janet E Rickard
John M D Storey
Karima Schwab
P2860
P304
P356
10.1097/FBP.0000000000000133
P577
2015-06-01T00:00:00Z